Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42716
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | STANDAERT, Baudouin | - |
dc.date.accessioned | 2024-03-27T14:04:37Z | - |
dc.date.available | 2024-03-27T14:04:37Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2024-03-27T12:17:13Z | - |
dc.identifier.citation | Vaccines, 11 (11) (Art N° 1646) | - |
dc.identifier.uri | http://hdl.handle.net/1942/42716 | - |
dc.description.abstract | Presently, there are at least five important vaccine producers that have already launched or intend to launch a new vaccine designed to prevent infections caused by the Respiratory Syncytial Virus (RSV), which is highly prevalent in the youngest as well as the oldest age groups [...]. | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.rights | 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | - |
dc.title | Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 2023, 11, 990 | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 11 | - |
dc.identifier.volume | 11 | - |
local.format.pages | 6 | - |
local.bibliographicCitation.jcat | A2 | - |
dc.description.notes | Standaert, B (corresponding author), Univ Hasselt, Fac Med & Life Sci, Dept Care & Eth, B-3590 Diepenbeek, Belgium.; Standaert, B (corresponding author), HEBO Bv, B-2020 Antwerp, Belgium. | - |
dc.description.notes | baudouin.standaert@uhasselt.be | - |
local.publisher.place | ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Editorial Material | - |
local.bibliographicCitation.artnr | 1646 | - |
dc.identifier.doi | 10.3390/vaccines11111646 | - |
dc.identifier.pmid | 38005978 | - |
dc.identifier.isi | WOS:001166851400001 | - |
dc.contributor.orcid | standaert, baudouin/0000-0001-6801-9654 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Standaert, Baudouin] Univ Hasselt, Fac Med & Life Sci, Dept Care & Eth, B-3590 Diepenbeek, Belgium. | - |
local.description.affiliation | [Standaert, Baudouin] HEBO Bv, B-2020 Antwerp, Belgium. | - |
local.uhasselt.international | no | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.contributor | STANDAERT, Baudouin | - |
item.fullcitation | STANDAERT, Baudouin (2023) Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 2023, 11, 990. In: Vaccines, 11 (11) (Art N° 1646). | - |
crisitem.journal.eissn | 2076-393X | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory w11, 990.pdf | Published version | 547.61 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.